---
title: "BridgeBio's Phase 3 trial of Oral Infigratinib in Achondroplasia shows significant body proportionality improvement, hitting primary endpoint (p<0.0001) - AHV at Week 52."
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275761690.md"
description: "The PROPEL 3 study achieved success by meeting the primary goal of demonstrating a significant change in AHV compared to baseline at Week 52, with a p-value of less than 0.0001."
datetime: "2026-02-12T12:56:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275761690.md)
  - [en](https://longbridge.com/en/news/275761690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275761690.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275761690.md) | [繁體中文](https://longbridge.com/zh-HK/news/275761690.md)


# BridgeBio's Phase 3 trial of Oral Infigratinib in Achondroplasia shows significant body proportionality improvement, hitting primary endpoint (p<0.0001) - AHV at Week 52.

The PROPEL 3 study achieved success by meeting the primary goal of demonstrating a significant change in AHV compared to baseline at Week 52, with a p-value of less than 0.0001.

### 相关股票

- [Bridgebio Pharma (BBIO.US)](https://longbridge.com/zh-CN/quote/BBIO.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)

## 相关资讯与研究

- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/zh-CN/news/278917368.md)
- [AbbVie reports topline data from Phase I ABBV-295 trial](https://longbridge.com/zh-CN/news/278540526.md)
- [Dyne Therapeutics Initiates Phase 3 Trial of Genetic Neuromuscular Disease Treatment](https://longbridge.com/zh-CN/news/278358809.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-CN/news/278556054.md)
- [BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress](https://longbridge.com/zh-CN/news/278878197.md)